Ravulizumab
Ravulizumab (ALXN1210) is a humanized monoclonal antibody that specifically binds with high affinity to the human complement protein C5. Ravulizumab can be used for the research of paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and myasthenia gravis[1].
Product Specifications
CAS Number
[1803171-55-2]
Product Name Alternative
ALXN1210
UNSPSC
12352203
Target
Complement System
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
Metabolism-protein/nucleotide metabolism
Field of Research
Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/ravulizumab.html
Purity
95.57
Solubility
H2O
Smiles
[Ravulizumab]
Molecular Weight
(145.8 kDa)
References & Citations
[1]Lee JW, et, al. Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study. Blood. 2019 Feb 7;133 (6) :530-539.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Launched
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
E9009-31D-APC 200 µL
Exportin 1, CT (XPO1, Chromosome Region Maintenance 1 Protein Homolog, CRM1, DKFZp686B1823, emb, Exp1, Exportin-1) (APC) discontinued
Ask
View Details 
